Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.
Theo LorenziniBruno Loureiro CadilhaHannah ObeckMohamed-Reda BenmebarekFlorian MärklStefanos MichaelidesThaddäus StrzalkowskiDaria BriukhovetskaPhilipp Jie MüllerSayantan NandiPia WinterLina MajedRuth GrünmeierMatthias SeifertSvenja RauschTobias FeuchtingerStefan EndresSebastian KoboldPublished in: British journal of cancer (2023)
PD-1-CD28 IFP constructs must mimic the physiological interaction of PD-1 with PD-L1 to retain selectivity and mediate CAR-conditional therapeutic activity.